| Symbol | AXSM |
|---|---|
| Name | AXSOME THERAPEUTICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 22 CORTLANDT STREET,16TH FLOOR, NEW YORK, New York, 10007, United States |
| Telephone | +1 212 332-3241 |
| Fax | — |
| — | |
| Website | https://www.axsome.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | — |
| Description | Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products include AXS-05, AXS-07, AXS-12, and AXS-14. Additional info from NASDAQ: |
Jacobson Mark L. 🟢 acquired 8.7K shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Apr 21, 2026 | Filing ID: 174419
Read moreTABUTEAU HERRIOT 🟢 acquired 24.1K shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Apr 21, 2026 | Filing ID: 174417
Read moreMaizel Ari 🟡 adjusted position in 7.5K shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) at $182.42 ($2.4M) Transaction Date: Apr 22, 2026 | Filing ID: 174415
Read moreMaizel Ari 🟢 acquired 7.2K shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Apr 21, 2026 | Filing ID: 174413
Read morePizzie Nick 🟢 acquired 8.2K shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Apr 21, 2026 | Filing ID: 174412
Read moreMurdock Hunter R. 🟢 acquired 7.2K shares (1 derivative) of Axsome Therapeutics, Inc. (AXSM) Transaction Date: Apr 21, 2026 | Filing ID: 174411
Read more📋 Maizel Ari (Officer) plans to sell 8K shares of Axsome Therapeutics, Inc. (at $182.42 each, total $1.4M) Filed: Apr 22, 2026 | ID: 000410
Read moreAxsome Therapeutics to Report First Quarter 2026 Financial Results on May 4
Read more(70% Positive) AXSOME THERAPEUTICS, INC. (AXSM) Announces Enrollment Update for mechanism Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review
Read moreAxsome Therapeutics Acquires Selective PDE10A Inhibitor Balipodect for the Treatment of Schizophrenia and Other Neuropsychiatric Conditions
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07398417 | Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal… | Phase3 | Fibromyalgia | Recruiting | 2026-01-14 | 2028-03-01 | ClinicalTrials.gov |
| NCT06878976 | Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder | Phase3 | Binge-Eating Disorder | Enrolling_By_Invitation | 2025-02-20 | 2026-12-01 | ClinicalTrials.gov |
| NCT06413433 | Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using… | Phase3 | Binge-Eating Disorder | Recruiting | 2024-04-26 | 2025-12-01 | ClinicalTrials.gov |
| NCT05838430 | Solriamfetol and CBT-I in Patients With Insomnia Disorder | Phase4 | Insomnia | Active_Not_Recruiting | 2023-07-31 | 2026-04-30 | ClinicalTrials.gov |
| NCT04788953 | Clinical Trial of Solriamfetol for Excessive Sleepiness Related to Shift Work D… | Phase4 | Excessive Sleepiness | Terminated | 2021-07-21 | 2024-04-19 | ClinicalTrials.gov |
| NCT04039022 | Open-Label Safety Study of AXS-05 in Subjects With Depression | Phase3 | Major Depressive Disorder | Completed | 2019-07-08 | 2020-10-23 | ClinicalTrials.gov |
| NCT04019704 | A Trial of AXS-05 in Patients With Major Depressive Disorder | Phase3 | Depression | Completed | 2019-06-20 | 2019-12-05 | ClinicalTrials.gov |
| NCT03226522 | Addressing Dementia Via Agitation-Centered Evaluation | Phase2 | Agitation in Patients With Dementia of the Alzheimer's Type | Completed | 2017-07-13 | 2020-04-17 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Solriamfetol 150 MG | DRUG | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| AXS-14 (Esreboxetine) | DRUG | Phase PHASE3 | Fibromyalgia | RECRUITING | NCT07398417 |
| Solriamfetol 75mg, 150 mg, or 300 mg | DRUG | Phase PHASE3 | Binge-Eating Disorder | ENROLLING_BY_INVITATION | NCT06878976 |
| No treatment | OTHER | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Other prescription wake-promoting medications or stimulants | DRUG | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Sunosi (solriamfetol) | DRUG | Preclinical | Narcolepsy | RECRUITING | NCT06413420 |
| Solriamfetol 300 mg | DRUG | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Solriamfetol 150 mg | DRUG | Phase PHASE3 | Excessive Sleepiness | RECRUITING | NCT06568367 |
| Monitoring | OTHER | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Cognitive Behavioral Therapy for Insomnia (CBT-I) | BEHAVIORAL | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| Solriamfetol 75 MG | DRUG | Phase PHASE4 | Insomnia | ACTIVE_NOT_RECRUITING | NCT05838430 |
| AXS-07 (meloxicam-rizatriptan) | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT05550207 |
| AXS-12 (reboxetine) | DRUG | Phase PHASE3 | Narcolepsy | COMPLETED | NCT05113745 |
| Solriamfetol 150 mg Oral Tablet | DRUG | Phase PHASE1 | Narcolepsy | COMPLETED | NCT05008341 |
| Solriamfetol | DRUG | Phase PHASE2 | Multiple Sclerosis | RECRUITING | NCT06170970 |
| Solriamfetol Oral Tablet | DRUG | Phase PHASE4 | Excessive Sleepiness | TERMINATED | NCT04788953 |
| AXS-05 (dextromethorphan-bupropion) | DRUG | Phase PHASE3 | Agitation in Patients With Dementia of the Alzheimer's Type | TERMINATED | NCT06736509 |
| AXS-07 | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT04068051 |
| AXS-05 (dextromethorphan and bupropion) oral tablets | DRUG | Phase PHASE3 | Major Depressive Disorder | COMPLETED | NCT04039022 |
| Rizatriptan | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| Meloxicam | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT03896009 |
| AXS-07 (MoSEIC meloxicam and rizatriptan) | DRUG | Phase PHASE3 | Migraine | COMPLETED | NCT04163185 |
| AXS-12 (Reboxetine) | DRUG | Phase PHASE2 | Narcolepsy | COMPLETED | NCT03881852 |
| Bupropion SR | DRUG | Phase PHASE2 | Major Depressive Disorder | UNKNOWN | NCT04971291 |
| AXS-02 | DRUG | Phase PHASE3 | Osteoarthritis, Knee | UNKNOWN | NCT02746068 |
| Bupropion | DRUG | Phase PHASE4 | Major Depressive Disorder | RECRUITING | NCT06223880 |
| AXS-05 | DRUG | Phase PHASE4 | Major Depressive Disorder | RECRUITING | NCT06223880 |
| Placebo | DRUG | Phase PHASE3 | Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms | RECRUITING | NCT07484217 |
| AXS-02 (oral zoledronate) | DRUG | Phase PHASE3 | Complex Regional Pain Syndrome | UNKNOWN | NCT02504008 |